40 results about "Fatty acid biosynthesis" patented technology

This document relates to methods and materials for generating oilseed (e.g., pennycress) plants that have oil with reduced levels of polyunsaturated fatty acids (PUFAs) and / or increased levels of oleic acid. For example, oilseed plants having reduced expression levels of one or more polypeptides involved in fatty acid biosynthesis (e.g., fatty acid desaturase 2 (FAD2) and reduced oleate desaturation 1 (ROD1)), as well as methods and materials for making and using such oilseed plants are provided.

The invention relates to the technical field of bioengineering, in particular to a saccharomyces cerevisiae engineering strain for producing caryophyllene and application of the saccharomyces cerevisiae engineering strain. The invention provides a saccharomyces cerevisiae engineering strain which has enhanced expression and / or activity of mevalonic acid pathway enzyme and one or more modifications selected from the following (1)-(2): (1) weakened expression and / or activity of sterol synthesis pathway enzyme; (2) attenuated expression and / or activity of fatty acid synthetic pathway enzymes; compared with an original strain, the saccharomyces cerevisiae engineering strain has the advantage that the sesquiterpene yield is increased. Compared with an original strain, the saccharomyces cerevisiae engineering strain has the advantages that the production capacity of the sesquiterpenes such as the caryophyllene is obviously improved, the sesquiterpenes such as the caryophyllene can be efficiently synthesized, and the saccharomyces cerevisiae engineering strain has better application value.

Combinations of fatty acid synthesis (FASN) inhibitors and glucagon-like peptide-1 (GLP-1) agonists for treating NAFLD / MAFLD, NASH / MASH, liver fibrosis and / or liver cirrhosis.

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

The invention discloses a difunctional alcohol dehydrogenase derived from Geobacillus thermodenitrifis, the difunctional alcohol dehydrogenase takes NAD < + > as a cofactor, can specifically catalyze a continuous oxidation reaction of omega-hydroxy fatty acid, and catalyzes the omega-hydroxy fatty acid to synthesize alpha, omega-binary fatty acid through single enzyme catalysis without an aldehyde intermediate. The alcohol dehydrogenase has dual catalytic functions of alcohol oxidation and aldehyde oxidation, the oxidation process from hydroxymethylene to carboxyl can be completed in one step, the reaction steps are simplified, accumulation and separation of intermediate aldehyde are avoided, the conversion efficiency is improved, and the alcohol dehydrogenase is alpha, omega-dibasic fatty acid and is a novel alcohol dehydrogenase. The invention provides a simple and efficient biocatalysis way for biosynthesis of dodecanedioic acid, especially dodecanedioic acid, and has important industrial application value.

The invention provides a composition, cell culture and application of the composition in differentiation of human pluripotent stem cells to myocardial cells and / or construction of human-derived heart organoid, and belongs to the technical field of cell engineering. The invention provides a composition. The composition comprises a fatty acid receptor antagonist, a fatty acid synthetase inhibitor and a fatty acid oxidation activator. The composition provided by the invention can regulate cell metabolism, breaks through the contradiction that the proliferation capacity and the cell maturity cannot be obtained at the same time in the traditional technology, can maintain the myocardial cells in a proliferation stage, and obtains the myocardial cells with relatively mature structures and functions, and the contractility of 3D heart organs constructed by the myocardial cells is greatly improved. The invention provides a high-quality cell source for myocardial regeneration treatment, high-throughput drug cardiotoxicity screening and heart disease mechanism research, and has remarkable clinical application value and industrialization prospect.

The invention relates to the technical field of agricultural herbicides, and discloses a herbicide suitable for cnidium monnieri planting in southern districts and a preparation method thereof, the herbicide is composed of 4-8% by mass of nicosulfuron, 16-20% by mass of atrazine and 8-12% by mass of quizalofop-p-ethyl, and the balance is water. The mass ratio of nicosulfuron to atrazine is (1: 3)-(1: 5). The nicosulfuron and the atrazine have a dual mechanism of inhibiting the activity of acetolactate synthetase of weeds and blocking photosynthesis, the control effect within 30 days after application reaches 85% or above, gramineae weeds such as digitaria sanguinalis and barnyard grass and broadleaf weeds such as chenopodium album and amaranth can be effectively prevented and removed, only slight phytotoxicity such as transient leaf chlorosis is caused to cnidium monnieri plants, and the effect is remarkable. The quizalofop-p-ethyl inhibits the activity of weed acetyl-coenzyme A carboxylase and blocks fatty acid synthesis, and has a good control effect on green bristlegrass, eleusine indica and other grassy weeds.

The invention relates to application of PFOI in preparation of a medicine for inducing tumor cell ferroptosis, and belongs to the technical field of medicine. The invention provides application of PFOI in preparation of a medicine for inducing tumor cell ferroptosis. The invention verifies the correlation between PFOI and tumor cell ferroptosis through experiments, and proves that PFOI can cause cancer cell mitochondrial atrophy, membrane density increase and mitochondrial ridge reduction; the ROS of cancer cells is increased; regulating cancer cell GSH metabolism and fatty acid biosynthesis, resulting in GSH depletion and lipid deposition; the ferroptosis of cancer cells is promoted by inhibiting the expression of the SLC7A11. On the basis, the invention provides a new application of PFOI in inducing tumor cell ferroptosis, an experimental basis and a new treatment strategy are provided for clinical treatment of cancers, and a new technical support is provided for targeted treatment of cancers.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The present disclosure relates to an antiviral pharmaceutical composition including an estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. According to embodiments of the present disclosure, an antiviral pharmaceutical composition containing an ERRγ inhibitor as an active ingredient has antiviral effects. In particular, the antiviral pharmaceutical composition is effective in preventing or treating RNA virus infections. Specifically, the ERRγ inhibitor, especially an ERRγ inverse agonist, may exhibit broad-spectrum antiviral effects by inhibiting ERRγ activity in RNA virus-infected cells, thereby blocking fatty acid biosynthesis mediated by sterol regulatory element-binding protein 1c (SREBP1c).

The application provides application of a LuPDH-E1beta1 gene in regulating plant fatty acid synthesis, and after overexpression of the LuPDH-E1beta1 gene in plants, the amount of plant fatty acid synthesis can be increased. The application also provides application of the LuPDH-E1beta1 gene in regulating plant salt tolerance and drought resistance, and after overexpression of the LuPDH-E1beta1 gene in plants, the salt tolerance and drought resistance of a PDH-E1beta1 gene deletion plant can be increased. Through exploration of the function of the LuPDH-E1beta1 gene in plant seed oil metabolism and response to abiotic stress, the application of the LuPDH-E1beta1 gene in regulating plant fatty acid synthesis and salt tolerance and drought resistance is given, and a blank in the application of the LuPDH-E1beta1 gene in genetic engineering is filled.

This invention discloses a GhLACS4 gene that regulates the oil content of plant seeds and its applications, belonging to the field of molecular biology. The nucleotide sequence of the GhLACS4 gene is shown in SEQ ID NO.1, and the amino acid sequence of its encoded protein is shown in SEQ ID NO.2. This gene mainly participates in fatty acid synthesis and affects the accumulation of oil in seeds by converting free fatty acids 18:2 into 18:2-CoA, thus providing gene resources for breeding high-oil cotton.

The invention discloses an application of idometacin in preparation of a cellular immunomodulator. According to the present invention, the endophytic fungus Endomelanconiopsis sp. GLQ07 of Ganoderma lucidum is subjected to separation and identification so as to obtain the endophytic fungus Endomelanconiopsis sp. On the premise of not influencing differentiation of other T cell subpopulations, the EpA can selectively enhance Th9 cell differentiation, significantly promote cytotoxic phenotype formation, improve mitochondrial functions and improve metabolic adaptability. Mechanism research shows that EpA acts on ZAP70 (TCR signal transduction key kinase) and SREBP1 (lipid metabolism main regulatory factor) through double-target synergistic action, and functional integration of TCR signal amplification and fatty acid synthesis inhibition is realized jointly. Functionally, the Th9 cell treated by EpA induces a strong CD8 + T cell dependent anti-tumor immune response in a preclinical model, and the treatment effect of the human Th9CAR-T cell is remarkably improved. The research results clearly show that EpA is a T cell immunomodulator with clinical application prospects and has remarkable technical value and industrialization potential.

The present invention discloses a genetically engineered Schizochytrium strain for efficient DHA production, as well as a construction method and application. The genetically engineered strain is obtained by knocking out the peroxisome matrix protein gene PEX10 in the wild-type Schizochytrium, which disrupts the β-oxidation pathway and blocks the degradation of fatty acyl-CoA; overexpressing the acetyl-CoA carboxylase gene ACC1 to provide more malonyl-CoA precursors, thereby promoting fatty acid biosynthesis; and overexpressing the diacylglycerol acyltransferase gene DGAT to promote the accumulation of fatty acids in the form of triglycerides. Under shake flask conditions, after fermentation, the DHA and PUFA produced reached 55.10% and 70.47% of the total oil content, respectively. Compared with the wild-type strain, DHA and PUFA increased by 21.6% and 24.77%, respectively, without a significant change in biomass, showing extremely high application potential.

The present application relates to an antiviral pharmaceutical composition comprising an estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The antiviral pharmaceutical composition comprising an ERRγ inhibitor as an active ingredient, according to embodiments of the present application, has an antiviral effect, and in particular, can exhibit the effect of preventing or treating RNA viral infection. Specifically, the ERRγ inhibitor, particularly an ERRγ inverse agonist, inhibits ERRγ activity in cells infected with RNA virus, thereby blocking SREBP1c-mediated fatty acid biosynthesis, and thus can exhibit broad-spectrum antiviral efficacy.

The present invention discloses the application of fatty acid synthesis metabolic pathway inhibitors in the differentiation of definitive endoderm cells, and also discloses a culture medium and a culture method for the in vitro directed differentiation of mammalian pluripotent stem cells into definitive endoderm cells. The culture medium comprises a basal medium and an inhibitor of the fatty acid synthesis metabolic pathway; the culture method is to culture mammalian pluripotent stem cells using the above-mentioned culture medium to enable their directed differentiation into definitive endoderm cells. By adding the fatty acid synthesis metabolic pathway inhibitor Firsocostat or C75 to the basal medium, the present invention improves the efficiency of differentiating mammalian pluripotent stem cells into definitive endoderm cells. The differentiation method provided by the present invention has good repeatability and low cost, and improves the efficiency of differentiating mammalian pluripotent stem cells into definitive endoderm. This provides low-cost and highly efficient research materials for studying early embryonic development, organ transplantation, and drug screening, etc.

The invention discloses application of EIF3H in treatment of liver cancer. Research finds that MASH and hepatic fibrosis can be relieved by down-regulating fatty acid de novo synthesis of EIF3H, and tumorigenesis in an HCC mouse model induced by DEN + HFHC and HDTI + HFHC is inhibited. In mechanism, EIF3H is combined with FASN, and KEAP1 mediated FASN ubiquitination is antagonized, so that the FASN protein is stabilized. Therefore, EIF3H is a FASN deubiquitinase which is not illuminated previously, and drives the MASLD-HCC process by promoting fatty acid metabolism reprogramming. The EIF3H-FASN axis can be used as a therapeutic target of liver cancer.

The invention discloses a fatty acid metabolism regulation gene mining method based on transcriptome data driving, a FindGene platform developed by the invention can efficiently integrate and standardize large-scale RNA-Seq data, systematic mining function related genes are analyzed through a weighted gene co-expression network, and the gene mining efficiency is improved. The limitation of dependence on small-scale experiments and manual screening in the past is broken through, and the efficiency and accuracy of key regulation gene screening are greatly improved. According to the schizosaccharomyces cerevisiae engineering strain QH-7 constructed by carrying out site-directed mutagenesis, overexpression and combined transformation on a key gene obtained by screening, the yield of fatty acid reaches 2.12 g / L and is increased by about 118.6% compared with that of a wild strain, and the biosynthesis efficiency of the fatty acid is greatly improved. According to the modified strain, the total fatty acid content is increased, meanwhile, the proportion of unsaturated fatty acids (C16: 1, C18: 1 and C18: 2) is remarkably increased, and the requirements for high-quality lipid raw materials in the fields of downstream biofuels, nutritional supplements and the like are met.

To provide use of isorhamnetin or pharmaceutically acceptable salts thereof in preparation of drugs for treating esophageal cancer in the technical field of biological medicines.SOLUTION: It has been found that isorhamnetin significantly inhibits malignant growth of metastatic esophageal squamous carcinoma cells and in-vivo ESCC metastatic tumors by inhibiting a fatty acid de novo synthesis pathway in tumor metabolism. Therefore, isorhamnetin can be used for developing an anti-ESCC metastatic cell growth medicine targeting an abnormally active fatty acid de novo anabolic enzyme.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of aquatic feed application, and discloses the application of ethanol clostridial protein in promoting the growth of Penaeus vannamei and improving intestinal flora. The invention takes Penaeus vannamei as the research object, studies the influence of ethanol clostridial protein as a partial replacement source of fish meal on Penaeus vannamei, and finds that it has a positive influence on the growth performance, immune performance, muscle fatty acid synthesis, intestinal flora and other aspects of Penaeus vannamei, thereby providing a theoretical basis for realizing ethanol clostridial protein as a partial replacement source of fish meal.

The application relates to application of PFOI in preparation of a tumor cell ferroptosis-inducing drug and belongs to the technical field of medicines. The application provides application of PFOI in preparation of a tumor cell ferroptosis-inducing drug. The application verifies the correlation between PFOI and tumor cell ferroptosis through experiments, proves that PFOI can cause mitochondrial atrophy, membrane density increase and mitochondrial cristae reduction of cancer cells, cause ROS increase of the cancer cells, regulate GSH metabolism and fatty acid biosynthesis of the cancer cells, cause GSH exhaustion and lipid deposition, and promote the cancer cells to occur ferroptosis by inhibiting the expression of SLC7A11. Based on this, the application provides a new use of PFOI for inducing tumor cell ferroptosis, provides experimental basis and a new treatment strategy for clinical treatment of cancer, and provides new technical support for targeted treatment of cancer.

Methods of treating NASH / MASH comprising administering a fatty acid synthesis (FASN) inhibitor and compositions for treating the same are provided herein.

The present invention belongs to the technical field of cosmetics, and discloses a composition for inhibiting sebum secretion and shrinking pores, as well as a preparation method and application. The composition of the present invention comprises the following components: angustifolia extract, kudzu root extract, plankton extract, olive leaf extract and medicinal pore fungus extract. The composition of the present invention is obtained by compounding angustifolia extract, kudzu root extract, plankton extract, olive leaf extract and medicinal pore fungus extract. On the basis of astringing pores, it innovatively combines the following pathways: reducing IGF-1-induced lipid synthesis, inhibiting acetyl-CoA carboxylase for de novo fatty acid synthesis, and down-regulating COX-2 gene expression. These multiple pathways work together to achieve the purpose of long-term inhibition of sebum secretion and shrinking pores.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

The invention discloses an Eriocheir sinensis ELOVL7 gene and application thereof, the nucleotide sequence of the Eriocheir sinensis ELOVL7 gene is as shown in SEQ ID NO: 1, and the amino acid sequence of protein encoded by the Eriocheir sinensis ELOVL7 gene is as shown in SEQ ID NO: 2. The Eriocheir sinensis ELOVL7 gene sequence is successfully obtained through a PCR technology for the first time, the function of the ELOVL7 gene is verified through an in-vitro experiment, it is proved that the gene serves as an elongase gene to play a role in the Eriocheir sinensis fatty acid synthesis process, the function of promoting LC-PUFA synthesis is achieved, a foundation is laid for studying the LC-PUFA anabolism mechanism of the Eriocheir sinensis, and the Eriocheir sinensis ELOVL7 gene has a good application prospect. And a reference is provided for the functional research of other crustacean ELOVL7.

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).

The present invention relates to the field of fatty acid synthesis and polyketone compound synthesis as well as protein engineering. In particular, it relates to providing engineered acyltransferases with altered substrate specificity, as well as means and methods of using the acyltransferases of the invention for polyketide synthesis.

Therapeutic combinations of a fatty acid synthesis modulator and a thyroid hormone receptor agonist are provided. The combinations are useful in the treatment of conditions, including metabolic conditions and liver conditions, such as non-alcoholic steatohepatitis / metabolic dysfunction associated steatohepatitis (NASH / MASH).

The invention discloses a GhLACS4 gene for adjusting the oil content of plant seeds and application of the GhLACS4 gene, and belongs to the technical field of molecular biology. The nucleotide sequence of the GhLACS4 gene is as shown in SEQ ID NO.1, and the amino acid sequence of the encoded protein of the GhLACS4 gene is as shown in SEQ ID NO.2. The gene mainly converts free fatty acid 18: 2 into 18: 2-CoA, further participates in synthesis of fatty acid to influence oil accumulation in seeds, and provides a gene resource for high-oil cotton breeding.

The invention belongs to the technical field of plant molecular biology, and particularly relates to a perilla frutescens PfLACS1 gene for regulating and controlling vegetable fat synthesis, a recombinant expression vector, recombinant bacteria and application, and the nucleotide sequence of the perilla frutescens PfLACS1 gene is shown as SEQ ID NO.1; the perilla key enzyme differential expression gene PfLACS1 is screened and identified for the first time, a molecular biology means is used for constructing a recombinant overexpression vector of the perilla PfLACS1 gene, the recombinant overexpression vector is converted into a yeast strain, the total oil content of overexpression yeast is analyzed, and the result shows that the perilla PfLACS1 gene can remarkably improve the total oil content of tobacco plant leaves. Theoretical reference is provided for further understanding of a perilla fatty acid synthesis accumulation mechanism and improvement of perilla oil yield and quality, and meanwhile, an excellent gene element is provided for specific enrichment of target fatty acid for other oil crops through a gene engineering technology.